Drug approvals this year have reflected the trend in clinical development of biologics shifting from intravenous to ...

Basel, 14 November 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Weekly ...

Cevostamab demonstrated a 38.8% overall response rate in relapsed/refractory multiple myeloma, with a median response duration of 12.3 months. BCMA-naive patients showed a higher overall response rate ...

An autoinjector to administer Leqembi to patients with early-stage Alzheimer’s disease had high degrees of satisfaction for utility, feasibility and convenience for use at home, according to a poster.

ORLANDO, Fla.--(BUSINESS WIRE)-- Millennium: The Takeda Oncology Company today reported results from a randomized, international Phase III clinical trial comparing subcutaneous and intravenous ...

MORRISVILLE, N.C., May 24, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today announced that Sandoz Treprostinil Injection, a generic form of Remodulin®, ...

Some experts believe offering a subcutaneous version of nivolumab could make PD-1 inhibitors available to new groups of patients who currently lack access, such as those in rural areas. This article ...

Roche is working closely with national health systems in Europe to ensure people with multiple sclerosis can access OCREVUS SC as quickly as possible Basel, 25 June 2024 - Roche (SIX: RO, ROG; OTCQX: ...

Please provide your email address to receive an email when new articles are posted on . Subcutaneous administration of a breast cancer therapy significantly decreased treatment time compared with IV ...

Immunotherapy, exemplified by Opdivo, enhances cancer treatment by targeting malignant cells using the immune system, offering a more precise approach than traditional therapies. The FDA approved ...

HYMPAVZI is currently approved in more than 40 countries for the treatment of eligible patients 12 years of age and older living with hemophilia A without factor VIII inhibitors, or hemophilia B ...